TABLE 3.

St and cost of resistance of mutations investigateda

MutationSt (±1 SE [10−2])bP valueCost per generation (%)Relative fitness (95% confidence interval)
Streptomycin
    RpsL 42 Arg−1.0 ± 1.50.480.9995.8-102.1
    RpsL 42 Asn−15.2 ± 1.9<0.0114.1079.9-89.6
    RpsL 42 Thr−16.2 ± 3.3<0.0114.9876.4-91.1
    rrn 522 Tc−9.3 ± 1.3<0.018.8888.0-93.3
    rrn 523 Cc−6.1 ± 1.5<0.015.9290.7-97.0
    rrn 523 Cd−5.4 ± 1.4<0.015.2691.4-97.7
    rrn 524 Cc−39.3 ± 5.1<0.0132.5044.5-77.0
    rrn 524 Cd−41.6 ± 2.9<0.0134.0351.4-65.4
    rrn 526 Tc−8.9 ± 1.8<0.018.5277.1-95.0
    rrn 526 Td−7.9 ± 0.9<0.017.6090.2-94.0
2-Deoxystreptamines
    rrn 1408Gc−1.7 ± 2.50.521.6992.6-104.1
    rrn 1408Gd−3.0 ± 2.20.132.9692.4-101.7
Macrolides
    rrn 2058Gc−2.0 ± 2.10.361.9893.4-102.6
    rrn 2059Gc−2.0 ± 3.40.571.9890.5-105.6
  • a Determined by analysis of variance (F test).

  • b Estimated by direct competition against an equal density of the drug-susceptible parental strain.

  • c Spontaneous mutants.

  • d Recombinant mutants.